- Home
- RYTM vs ASTS Comparison
RYTM vs ASTS Comparison
Compare RYTM & ASTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- ASTS
- Stock Information
- Founded
- RYTM 2008
- ASTS 2019
- Country
- RYTM United States
- ASTS United States
- Employees
- RYTM N/A
- ASTS N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- ASTS Telecommunications Equipment
- Sector
- RYTM Health Care
- ASTS Consumer Discretionary
- Exchange
- RYTM Nasdaq
- ASTS Nasdaq
- Market Cap
- RYTM 3.5B
- ASTS 4.1B
- IPO Year
- RYTM 2017
- ASTS N/A
- Fundamental
- Price
- RYTM $56.07
- ASTS $28.64
- Analyst Decision
- RYTM Strong Buy
- ASTS Strong Buy
- Analyst Count
- RYTM 10
- ASTS 5
- Target Price
- RYTM $66.90
- ASTS $40.04
- AVG Volume (30 Days)
- RYTM 380.5K
- ASTS 14.2M
- Earning Date
- RYTM 02-26-2025
- ASTS 03-03-2025
- Dividend Yield
- RYTM N/A
- ASTS N/A
- EPS Growth
- RYTM N/A
- ASTS N/A
- EPS
- RYTM N/A
- ASTS N/A
- Revenue
- RYTM $112,530,000.00
- ASTS $2,500,000.00
- Revenue This Year
- RYTM $66.58
- ASTS N/A
- Revenue Next Year
- RYTM $44.63
- ASTS $4,467.90
- P/E Ratio
- RYTM N/A
- ASTS N/A
- Revenue Growth
- RYTM 81.55
- ASTS N/A
- 52 Week Low
- RYTM $35.17
- ASTS $1.97
- 52 Week High
- RYTM $68.58
- ASTS $39.08
- Technical
- Relative Strength Index (RSI)
- RYTM 42.18
- ASTS 56.14
- Support Level
- RYTM $56.03
- ASTS $27.05
- Resistance Level
- RYTM $58.65
- ASTS $33.55
- Average True Range (ATR)
- RYTM 1.87
- ASTS 2.88
- MACD
- RYTM -0.27
- ASTS 0.49
- Stochastic Oscillator
- RYTM 5.45
- ASTS 66.58
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About ASTS AST SpaceMobile Inc.
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers and finally bringing broadband to the billions who remain unconnected. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.